<DOC>
	<DOCNO>NCT01440270</DOCNO>
	<brief_summary>Epidermal growth factor receptor（EGFR） potential target new anticancer therapy head neck squamous cell carcinoma , block EGFR monoclonal antibody result inhibition stimulation receptor , therefore , inhibition cell proliferation , enhance apoptosis , reduce angiogenesis , invasiveness metastasis . The study hypothesis neo-adjuvant Erbitux-based chemotherapy follow surgery radiotherapy locally advanced oral/oropharyngeal cancer could benefit patient prognosis . The endpoint study pathological complete response neo-adjuvant Erbitux-based chemotherapy follow surgery radiotherapy , survival rate , safety .</brief_summary>
	<brief_title>Neo-adjuvant Erbitux-based Chemotherapy Locally Advanced Oral/Oropharyngeal Cancer</brief_title>
	<detailed_description>The primary endpoint study pathological complete response neo-adjuvant Erbitux-based chemotherapy follow surgery radiotherapy . The second endpoint study disease free survival rate ( 1 , 2 , 3 , 5 year ) , locoregional control rate ( 1 , 3 , 5 year ) , overall survival rate ( 3 , 5 year ) , safety .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent prior study activity Age 1875 Histological/cytological iconography confirm squamouscelled oral/oropharyngeal cancer Stage Ⅲ/Ⅳa ( T12 , N12 , M0 T34 , N02 , M0 , AJCC 2010 ) , operable disease Karnofsky performance status ( KPS ) ≥ 70 Adequate hematologic function : Neutrophils ≥ 1,500/mm^3 , WBC &gt; 4,000/mm^3 , Hb &gt; 10 g/dL , platelet count &gt; 100,000/mm^3 Hepatic function : ALAT/ASAT &lt; 2.5 time upper limit normal ( ULN ) , bilirubin &lt; 1.5 x ULN Renal function : serum creatinine &lt; 1.5 x ULN Life expectancy ≥ 6 month Evidence distant metastatic disease oropharyngeal cancer Surgical procedure primary tumor lymph node ( except diagnostic biopsy ) study treatment Previous radiotherapy primary tumor lymph node Previous exposure epidermal growth factor target therapy Prior chemotherapy immunotherapy primary tumor Other previous malignancy within 5 year , except adequately treat nonmelanoma skin cancer preinvasive carcinoma cervix Any investigational agent prior 1st study medication Participation another clinical study within 30 day prior Inclusion study . Peripheral neuropathy &gt; grade 1 Known grade 3 4 allergic reaction study treatment Creatinine Clearance &lt; 30 ml/min Know drug abuse / alcohol abuse Legal incapacity limit legal capacity Active systemic infection Medical psychiatric illness , investigator ' opinion , would permit subject complete fully completely understand risk potential complication study Concurrent chronic systemic immune therapy hormone therapy indicate study protocol Pregnancy ( confirm serum urine βHCG ) lactation period Severe cardiac disease heart failure , clinically relevant cardiac dysrhythmias , coronary artery disease myocardial infarction within last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Oral cancer</keyword>
	<keyword>Oropharyngeal cancer</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Targeted chemotherapy</keyword>
	<keyword>Surgery</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Effects Chemotherapy</keyword>
</DOC>